What is the 13F Pro Quality Score for SNDX?

13F Pro ranks Syndax Pharmaceuticals Inc (SNDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SNDX's current score at https://13fpro.ai/company/SNDX (free sign-up required for the full ranking).

Which hedge funds own the most SNDX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SNDX include BlackRock,, Kynam Capital Management,, GOLDMAN SACHS GROUP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SNDX as soon as new 13F filings post.

Where does 13F Pro source SNDX data?

All Syndax Pharmaceuticals Inc fundamentals and ownership data come directly from SEC EDGAR. Syndax Pharmaceuticals Inc files with the SEC under CIK 1395937. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SNDX in?

Syndax Pharmaceuticals Inc (SNDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SNDX research updated on 13F Pro?

SNDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Syndax Pharmaceuticals Inc(SNDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1395937 SNDX stock profile & AI dashboard →

13F Pro Quality Score

33.8/100

Rank #2,378 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

8.2/100

Balance Sheet

6.6/100

Earnings Quality

10.3/100

Free Cash Flow

6.9/100

Institutional Flow

25.6/100

Revenue Scale

26.8/100

Dilution Risk

6.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SNDX Scores 34/100

exact factor attribution · 2026-09-11

SNDX's composite is driven by revenue growth and earnings growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

99th pct

Earnings growth

+1.8 pts

86th pct

Institutional flow

-1.2 pts

26th pct

Shareholder dilution

-2.2 pts

7th pct

Scale

-3.5 pts

27th pct

Earnings quality

-4.0 pts

10th pct

Capital efficiency

-4.3 pts

7th pct

Profitability

-6.3 pts

8th pct

Free cash flow

-6.5 pts

7th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SNDX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Syndax Pharmaceuticals Inc (SNDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SNDX at 33.8/100 on a 32-signal composite quality model, placing it at rank #2,378 of 2,962 stocks — the bottom half of the AI-ranked universe. SNDX scores in the top quartile across revenue growth (99.3). Areas of concern include balance sheet strength (6.6) and free cash flow (6.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Syndax Pharmaceuticals Inc reports quarterly revenue of $72.8M, net income of $-49.4M. Top institutional holders of SNDX by reported 13-F value include BlackRock, Kynam Capital Management, GOLDMAN SACHS GROUP, based on the most recent SEC filings. SNDX trades on the Nasdaq exchange and files with the SEC under CIK 1395937. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Syndax Pharmaceuticals Inc directly from SEC EDGAR. Syndax Pharmaceuticals Inc's 13F Pro composite quality score has ranged between 14 and 34 since 2021, currently 33.8 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about Syndax Pharmaceuticals Inc

Quirks, history, and lore behind SNDX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on oncology.
2
The Numbers
A small-cap with no product revenue yet — it runs on grants, partnerships, and the eternal optimism of biotech investors funding expensive cancer trials.
3
The History
Founded in the early 2000s, the company has spent two decades building a pipeline around a class of targets called epigenetic regulators, which control how genes get switched on and off in tumor cells.
4
The Secret
Its lead focus is on menin inhibitors — a relatively novel mechanism targeting certain leukemias driven by specific genetic mutations, putting it in a small club of companies chasing this approach.
5
The Lore
The company's pipeline also includes revumenib, an investigational menin inhibitor studied in acute leukemia patients who have run out of other options — a drug that drew genuine buzz at major hematology conferences.
6
The Giveaway
Ticker SNDX, headquartered in Watertown, MA — this is Syndax Pharmaceuticals, the epigenetics-focused oncology shop swinging for a cure one mutated leukemia cell at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$72.8M

Net Income

Q2 2026

$-49.4M

ROIC

Q2 2026

-22.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+627.8% YoY

$172.4MFY 2025

FY22 $0.00FY23 $0.00FY24 $23.7MFY25 $172.4M

Net Income

+10.5% YoY

$-285.4MFY 2025

FY22 $-149.3MFY23 $-209.4MFY24 $-318.8MFY25 $-285.4M

Operating Income

+19.6% YoY

$-273.1MFY 2025

FY22 $-151.8MFY23 $-230.0MFY24 $-339.7MFY25 $-273.1M

EPS (Diluted)

+11.6% YoY

$-3.29FY 2025

FY22 $-2.46FY23 $-2.98FY24 $-3.72FY25 $-3.29

Total Assets

-26.9% YoY

$529.7MFY 2025

FY22 $497.2MFY23 $612.9MFY24 $724.8MFY25 $529.7M

Total Debt

+1.8% YoY

$693.9MFY 2025

FY22 —FY23 $0.00FY24 $681.6MFY25 $693.9M

Op. Cash Flow

-17.5% YoY

$-323.0MFY 2025

FY22 $-133.7MFY23 $-160.6MFY24 $-274.9MFY25 $-323.0M

Free Cash Flow

-17.6% YoY

$-323.2MFY 2025

FY22 $-133.7MFY23 $-160.6MFY24 $-274.9MFY25 $-323.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$172.4M +627.8%	$23.7M	$0.00	$0.00 -100.0%	$139.7M +9109.6%	$1.5M
Net Income	$-285.4M +10.5%	$-318.8M -52.3%	$-209.4M -40.2%	$-149.3M -699.1%	$24.9M +134.1%	$-73.2M
Operating Income	$-273.1M +19.6%	$-339.7M -47.7%	$-230.0M -51.5%	$-151.8M -678.8%	$26.2M +136.7%	$-71.4M
EPS (Diluted)	$-3.29 +11.6%	$-3.72 -24.8%	$-2.98 -21.1%	$-2.46 -634.8%	$0.46 +124.6%	$-1.87
Total Assets	$529.7M -26.9%	$724.8M +18.3%	$612.9M +23.3%	$497.2M +10.6%	$449.7M +49.6%	$300.6M
Total Debt	$693.9M +1.8%	$681.6M	$0.00	—	—	—
Operating Cash Flow	$-323.0M -17.5%	$-274.9M -71.2%	$-160.6M -20.1%	$-133.7M -558.9%	$29.1M +140.9%	$-71.3M
Free Cash Flow	$-323.2M -17.6%	$-274.9M -71.2%	$-160.6M -20.1%	$-133.7M -560.9%	$29.0M +140.7%	$-71.3M

Get alerted when SNDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Syndax Pharmaceuticals Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SNDX

BlackRock, Inc.
$197.2M9,020,006 sh
Kynam Capital Management, LP
$176.0M8,050,959 sh
GOLDMAN SACHS GROUP INC
$128.1M5,861,265 sh
STATE STREET CORP
$123.7M5,658,424 sh
BANK OF AMERICA CORP /DE/
$88.4M4,045,094 sh
VANGUARD CAPITAL MANAGEMENT LLC
$85.9M3,927,892 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$82.6M3,779,900 sh
Eversept Partners, LP
$61.2M2,798,210 sh
GEODE CAPITAL MANAGEMENT, LLC
$56.5M2,584,136 sh
Hood River Capital Management LLC
$56.1M2,564,279 sh

Fund	Value	Shares
BlackRock, Inc.	$197.2M	9,020,006
Kynam Capital Management, LP	$176.0M	8,050,959
GOLDMAN SACHS GROUP INC	$128.1M	5,861,265
STATE STREET CORP	$123.7M	5,658,424
BANK OF AMERICA CORP /DE/	$88.4M	4,045,094
VANGUARD CAPITAL MANAGEMENT LLC	$85.9M	3,927,892
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$82.6M	3,779,900
Eversept Partners, LP	$61.2M	2,798,210
GEODE CAPITAL MANAGEMENT, LLC	$56.5M	2,584,136
Hood River Capital Management LLC	$56.1M	2,564,279

Companies Similar to SNDX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

URGN

UroGen Pharma Ltd.

AI score

Very similar · 13 shared holders

Kynam Capital Management, LP SILVERARC CAPITAL MANAGEMENT, LLC Soleus Capital Management, L.P.

KURA

Kura Oncology, Inc.

AI score

Very similar · 17 shared holders

Prosight Management, LP Rhenman & Partners Asset Management AB Hennion & Walsh Asset Management, Inc.

BBIO

BridgeBio Pharma, Inc.

AI score

Very similar · 14 shared holders

Hood River Capital Management LLC Aisling Capital Management LP Catalio Capital Management, LP

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Very similar · 17 shared holders

Candriam S.C.A.Hood River Capital Management LLC Trails Edge Capital Partners, LP

AGIO

AGIOS PHARMACEUTICALS, INC.

AI score

Very similar · 12 shared holders

Parkman Healthcare Partners LLC Palo Alto Investors LP Knott David M Jr

IMCR

Immunocore Holdings plc

AI score

Very similar · 14 shared holders

Kynam Capital Management, LP DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Trails Edge Capital Partners, LP

CYTK

CYTOKINETICS INC

AI score

Very similar · 16 shared holders

Hood River Capital Management LLC Candriam S.C.A.Trails Edge Capital Partners, LP

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Similar quality profile · 13 shared holders

Kynam Capital Management, LP Candriam S.C.A.Parkman Healthcare Partners LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SNDX on your watchlist

Track score changes the day Syndax Pharmaceuticals Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SNDX a good stock to buy?

13F Pro's AI-powered analysis of Syndax Pharmaceuticals Inc (SNDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNDX are available on the SNDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SNDX is classified as a small company.

Which hedge funds own SNDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Syndax Pharmaceuticals Inc's investment landscape.